Startseite Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C15H13NO3
Artikel Open Access

Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C15H13NO3

  • Smaail Radi , Said Tighadouini , Driss Eddike , Yahia N. Mabkhot und Monique Tillard EMAIL logo
Veröffentlicht/Copyright: 18. Januar 2017

Abstract

C15H13NO3, monoclinic, Cc (No. 9), a = 3.9230(3) Å, b = 26.578(2) Å, c = 11.7147(12) Å, β = 94.028(8)°, V = 1218.4(2) Å3, Z = 4, Rgt(F) = 0.0387, wRref(F2) = 0.0877, T = 173 K.

CCDC no.:: 1525410

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless platelet
Size:0.50 × 0.15 × 0.06 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:1.0 cm−1
Diffractometer, scan mode:Xcalibur Sapphire3, ω-scans
2θmax, completeness:58.6°, >87%
N(hkl)measured, N(hkl)unique, Rint:6523, 2714, 0.024
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2410
N(param)refined:181
Programs:CrysAlisPRO [8], SHELX [9], ORTEP [10]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C1−0.1882(5)−0.36669(8)−0.2671(2)0.0259(5)
C2−0.2952(6)−0.36593(9)−0.3825(2)0.0267(6)
C3−0.2108(5)−0.40601(8)−0.4539(2)0.0249(5)
C4−0.3192(6)−0.40770(8)−0.5771(2)0.0241(5)
C5−0.2310(6)−0.44855(8)−0.6429(2)0.0266(5)
H5−0.1015−0.4752−0.60740.032*
C6−0.3270(5)−0.45148(9)−0.7591(2)0.0269(6)
H6−0.2665−0.4799−0.80240.032*
C7−0.5126(5)−0.41221(9)−0.8110(2)0.0246(5)
C8−0.6015(6)−0.37083(9)−0.7473(2)0.0282(6)
H8−0.7275−0.3440−0.78340.034*
C9−0.5073(5)−0.36858(9)−0.6318(2)0.0268(5)
H9−0.5705−0.3402−0.58880.032*
C10−0.5131(6)−0.45106(9)−0.9946(2)0.0320(6)
H10A−0.6025−0.4831−0.96820.048*
H10B−0.2629−0.4523−0.99010.048*
H10C−0.5990−0.4451−1.07410.048*
C11−0.2740(6)−0.32595(8)−0.1876(2)0.0267(5)
C12−0.1731(6)−0.32924(9)−0.0722(2)0.0316(6)
H12−0.0481−0.3576−0.04270.038*
C13−0.2582(7)−0.29035(10)−0.0005(2)0.0368(6)
H13−0.1917−0.29150.07900.044*
C14−0.4396(6)−0.25025(10)−0.0461(2)0.0357(6)
H14−0.5014−0.22310.00100.043*
C15−0.5309(7)−0.25009(10)−0.1626(3)0.0360(6)
H15−0.6576−0.2222−0.19340.043*
H1−0.435(7)−0.3384(10)−0.409(2)0.032(7)*
H20.019(11)−0.4269(17)−0.312(4)0.099(14)*
N−0.4521(5)−0.28662(7)−0.23402(19)0.0314(5)
O1−0.0315(4)−0.44320(6)−0.41288(16)0.0320(4)
O2−0.0054(5)−0.40355(6)−0.22220(17)0.0348(4)
O3−0.6225(4)−0.41111(6)−0.92382(15)0.0310(4)

Source of material

To a suspension of sodium (0.4 g; 17.40 mmol) in anhydrous toluene, was added ethyl 2-picolinate (2 g; 13.28 mmol) in toluene. Then 1-(4-methoxphenyl) ethanone (1.99 g; 13.28 mmol) was added at 0 °C. The resulting mixture was stirred at room temperature for 7 days. The precipitate formed was filtered, washed and dissolved in water. The neutralized solution was extracted with CH2Cl2, and the organic layer was dried and concentrated in vacuo. The obtained residue was chromatographed on silica using CH2Cl2/MeOH as eluant to give the desired product. Crystals of the title compound were obtained from hot ethanol by slow evaporation. Yield: 33%, M.p. 112–114 °C.

Experimental details

The structure has been first solved in a triclinic unit cell of parameters a = 7.85, b = 11.72, c = 13.43 Å, α = 89.4, β = 81.6, γ = 86.0°. The unit cell contains four independant molecules. Final refinement in these conditions with anisotropic displacement parameters led to an agreement factor R1 = 4.59%. Except the freely refined H atoms that display rather high standard deviations for which positions are not precisely determined, the four molecules are symmetry-related and it became obvious that the cell must be transformed to the monoclinic cell described here (−.5 0 0 −.5 0 2 0 1 0). Final refinement in the monoclinic space group improves the agreement factor to 3.87%. The acidic hydrogen atom is placed between O1 and O2 atoms. This would indicate that this H atom is easily exchangeable between the two oxygen atoms.

Discussion

Compounds incorporating a β-ketoenol moiety have yielded clinical integrase inhibitor drug candidates [1]. Tomassini et al. reported a series of β-ketoenol derivatives as effective inhibitors drug of influenza viral replication in both in vitro cell culture replication assays and in vivo mouse challenge model, without exhibiting any cytotoxicity [2], [3], [4]. Furthermore, complexes with β-ketoenols have received more attention in the area of medicinal chemistry [5], exhibiting anticancer activity against several tumoral cells strains [6], and cytotoxic activity in a chronic myelogenous leukemia cell line [7]. Herein, we report the preparation of a new pyridine incorporating a β-ketoenol moiety: (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl) prop-2-en-1-one in moderate yield.

The crystal structure shows that the oxygen atoms share the same hydrogen atom placed just in between O1 and O2. This is due to the fact that each of the two atoms O1 and O2 alternately ensure the enole and ketone fonctions, and are involved in a tautomer effect as reflected by the close distances C3—O1 1.287(3) and C1—O2 1.303(3) Å. The C4, C5, C6, C7, C8 and C9 atoms are in the same plane. The torsion angle O1 C3 C4 C9 of 178.2(2)° indicates that the benzene ring undergoes slight inclination with respect to the C3—C4 bond. Also the 2-pyridinyl moiety are in the same plane, while the torsion angle O2—C1—C11—N of −177.5(2)° indicate that the plane of pyridine ring undergoes also a slight inclination relative to plane of the rest of the molecule.

Acknowledgements

The authors extend their appreciation to the PPR2-MESRSFC-CNRST-P10 project (Morocco). Sincere appreciation was also extended to the Deanship of Scientific Research at King Saud University for its supporting this Prolific Research group (PRG-1437–29).

References

1 Dayam, R.; Deng, J.; Neamati, N.: HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev. 26 (2006) 271–309.10.1002/med.20054Suche in Google Scholar PubMed

2 Tomassini, J. E.; Selnick, H.; Davies, M. E.; Armstrong, M. E.; Baldwin, J.; Bourgeois, M.; Hastings, J.; Hazuda, D.; Lewis, J.; McClements, W.: Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob. Agents Chemother. 38 (1994) 2827–2837.10.1128/AAC.38.12.2827Suche in Google Scholar PubMed PubMed Central

3 Tomassini, J. E.; Davies, M. E.; Hastings, J. C.; Lingham, R.; Mojena, M.; Raghoobar, S. L.; Singh, S. B.; Tkacz, J. S.; Goetz, M. A.: A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob. Agents Chemother. 40 (1996) 1189–1193.10.1128/AAC.40.5.1189Suche in Google Scholar PubMed PubMed Central

4 Hastings, J. C.; Selnick, H.; Wolanski, B.; Tomassini, J. E.: Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob. Agents Chemother. 40 (1996) 1304–1307.10.1128/AAC.40.5.1304Suche in Google Scholar PubMed PubMed Central

5 Almeida, J. C.; Marzano, I. M.; Silva de Paula, F. C.; Pivatto, M.; Lopes, N. P.; deSouza, P. C.; Pavan, F. R.; Formiga, A. L. B.; Pereira-Maia, E. C.; Guerra, W.: Complexes of platinum and palladium with β-diketones and DMSO: Synthesis, characterization, molecular modeling, and biological studies. J. Mol. Struct. 1075 (2014) 370–376.10.1016/j.molstruc.2014.07.023Suche in Google Scholar

6 Wilson, J. J.; Lippard, S. J.: In vitro anticancer activity of cis-diammineplatinum(II) complexes with β-diketonate leaving group ligands. J. Med. Chem. 55 (2012) 5326–5336.10.1021/jm3002857Suche in Google Scholar PubMed PubMed Central

7 Almeida, J. D. C.; Paixao, D. A.; Marzano, I. M.; Ellena, J.; Pivatto, M.; Lopes, N. P.; Ferreira, A. M. D. C.; Pereira-Maia, E. C.; Guilardi, S.; Guerra, W.: Copper(II) complexes with β-diketones and N-donor heterocyclic ligands: Crystal structure, spectral properties, and cytotoxic activity. Polyhedron 89 (2015) 1–8.10.1016/j.poly.2014.12.026Suche in Google Scholar

8 Rigaku Oxford Diffraction. CrysAlis PRO Software system, version 1.171.38.41, Rigaku Corporation, Oxford, UK, 2016.Suche in Google Scholar

9 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

10 Farrugia, L. J.: WinGX, ORTEP for Windows, an update. J. Appl. Crystallogr. 45 (2012) 849–854.10.1107/S0021889812029111Suche in Google Scholar

Received: 2016-7-27
Accepted: 2017-1-3
Published Online: 2017-1-18
Published in Print: 2017-3-1

©2017 Smaail Radi et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. The crystal structure of triphenylphosphineoxide – 2,5-dichloro-3,6-dihydroxycyclohexa-2,5-diene-1,4-dione (2/1), C42H32Cl2O6P2
  3. Crystal structure of poly-[diaqua-[bis(μ2-hydroxy)-bis(μ4-3,4,5,6-tetrachlorophthalato-κ3O,O′:O′; κ2O′′:O′′′)dilanthanum(III)], C8H3Cl4LaO6
  4. Crystal structure of 1,1′-(3,4-diphenylthieno[2,3-b]thiophene-2,5-diyl)bis[1-phenyl-methanone], C32H20O2S2
  5. Crystal structure of 4a-hydroxy-9-(3,5-dibromo-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H18Br2O4
  6. Crystal structure of 5-hydroxy-4,6,9,10-tetramethyl-1-oxo-6-vinyldecahydro-3a,9-propanocyclopenta[8]annulen-8-yl 2-((2-methyl-1-(3-methylbenzamido)propan-2-yl)thio)acetate, C34H49NO5S
  7. Crystal structure of pyridinium bis(naphthalane-2,3-diolato-κ2O,O′)borate monohydrate, C25H20BNO5
  8. Crystal structure of 1,1′-((1E,1′E)-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(naphthalen-2-olato)nickel(II), C72H52N4O8Ni2
  9. The crystal structure of 3-(2-acetyl-4-butyramido-phenoxy)-2-hydroxy-N-isopropylpropan-1-aminium tetraphenylborate, C42H49BN2O4
  10. Crystal structure of 4-bromobenzyl (Z)-N′-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioimidate, C28H34BrN3S
  11. Crystal structure of poly-[(μ6-benzene-1,2,4,5-tetracarboxylato)-(μ2-1,2-bis(imidazol-1-ylmethyl)benzene)dicobalt(II)], Co2C24H16N4O8
  12. Crystal structure of catena-(bis(μ2-1, 2-bis(imidazole-1-ylmethyl)benzene-κN:N′)-dichlororido-nickel(II)), C28H28Cl2N8Ni
  13. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(4-methoxyphenyl)prop-2-en-1-one, C15H16N2O3
  14. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, C14H14N2O2
  15. Crystal structure of (E)-2-(4-hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H18O4
  16. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(4-ethoxyphenyl)-3-hydroxyprop-2-en-1-one, C16H18N2O3
  17. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(p-toly)prop-2-en-1-one, C15H16N2O2
  18. Crystal structure of 1-acetyl-3-(3-chlorophenyl)-5-(4-isopropylphenyl)-4,5-dihydro-(1H)-pyrazole, C20H21ClN2O
  19. The crystal structure of 1-methyl-2,4-dinitro-5-iodoimidazole, C4H3IN4O4
  20. The crystal structure of 4-chloro-3,5-dinitroaniline, C6H4ClN3O4
  21. Crystal structure of N,N-dimethyl-N′-(2-methyl-4-oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)formimidamide, C14H18N4OS
  22. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis[μ3-4-chloro-2,6-bis((methylimino)methyl)phenolato-κ2N,O:O,N′]-(μ4-oxido)tetracopper(II), C28H32Cl2Cu4N4O11
  23. Crystal structure of catena-poly[diaqua-bis(μ2-ethane-1,2-diyl-bis(pyridine-3-carboxylate-κ2N:N′))copper(II)] dinitrate, C28H28CuN6O16
  24. Synthesis and crystal structure of catena-poly[(μ2-nicotinato-κ2O,O′: κ1N)-(nitrato-κ1O)-(bis(2-benzimidazol-ylmethyl)amine-κ3N,N′,N′′)lead(II)], C22H18N7O5Pb
  25. The twinned crystal structure of (4SR)-7-benzyl-2,4,8,8-tetramethyl-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione, C16H20N4O2
  26. Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C15H13NO3
  27. Crystal structure of 2-amino-4-(2,3-dichlorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H12Cl2N2O2
  28. Crystal structure of catena-poly[(μ2-butane-1,4-diyl-bis(pyridine-3-carboxylato-κN))silver(I)] tetrafluoroborate, C16H16AgN2O4BF4
  29. Crystal structure of poly[diaqua-(1,10-phenanthroline-κ2N,N′)-(μ2-2,5-dihydroxytere-phthalato)-bis(μ4-2,5-dihydroxyterephthalato)dicerium(III)], C24H16CeN2O10
  30. Crystal structure of 5,7,4′-trihydroxy-3,8,3′-trymethoxyflavone, C18H16O8
  31. Crystal structure of N-(3,4-dichlorobenzylidene)-4-methylaniline, C14H11Cl2N
  32. Crystal structure of 4-(3-Methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C22H27NO4
  33. Crystal structure of 2-amino-4-(3-fluorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13FN2O2
  34. Crystal structure of 1,1,(3,4-dihydroxythieno[2,3-b] thiophene-2,5-diyl)bis(2-bromoethanone), C10H6Br2O4S2
  35. The crystal structure of N,N′-(4,4′-oxydibenzyl)-bisisonicotinamide 3.5 hydrate, C24H24N4O6
  36. Crystal structure of catena-poly[hexakis(μ2-chlorido)-hexakis(4-(1H-pyrazol-5-yl)pyridine-κN)tricadmium(II)], Cd3C48H42Cl6N18
  37. Crystal structure of 2-(4-(dimethylamino)phenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C21H22I1N3
  38. Crystal structure of 4-(1,3-dimethyl-2,3-dihydro-1H-perimidin-2-yl)benzonitrile, C20H17N3
  39. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis(2,2′-sulfonyldipyrazine-κ1N)dicopper(II), C24H24Cu2N8O12S2
  40. Crystal structure of 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinoline, C28H18ClN3
  41. Crystal structure of methyl 3-((1-(2-(methoxycarbonyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-naphthoate, C24H21N3O5
  42. Crystal structure of (tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′′)-chloranilato-κO,O′-zinc(II) – methanol (1/1), C25H22Cl2N4O5Zn
  43. Crystal structure of 1,1-dimethyl-3-(4-methoxyphenyl)urea, C10H14N2O2
  44. Crystal structure of 4a-Hydroxy-9-(2-nitro-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H19NO6
  45. Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu
  46. Crystal structure of phenyl(2-phenyl-2,3-dihydro-1H-perimidin-2-yl)methanone, C24H18N2O
  47. Crystal structure of (E)-3-methyl-4-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1-phenyl-1H-pyrazol-5(4H)-one, C29H23N7O
  48. Crystal structure of 2-(4-(2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)piperazin-1-yl)-2-oxoethyldiethylcarbamodithioate, C27H34N4O3S2
  49. Crystal structure of poly-[diaqua-bis(μ-4,4′-bipyridine-κ2N:N′)cobalt(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2), C42H40Cl2CoN6O10S2
  50. Crystal structure of (η6-benzene)-(N-(2,6-dimethylphenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) perchlorate monohydrate, C20H20Cl2N2O5Ru
  51. Crystal structure of 4,10,16,22-tetrahydroxy-6,12,18,24-tetramethoxy-2,8,14,20-tetraethylphenylresorcin[4]arene – ethyl acetate (1/1), C68H72O10
  52. Crystal structure of chlorido-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)(η6-1-isopropyl-4-methyl benzene) ruthenium (II) tetrafluoroborate, C22H22Cl3N2BF4Ru
  53. Crystal structure of 3-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde, a rare Z′ = 3 structure, C20H17N5O
  54. Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)-N-phenyl-1,3,4-thiadiazol-2-amine, C23H16ClN5S
  55. Crystal structure of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one-N,N-dimethylformamide (1/1), C18H17NO5
  56. Crystal structure of halogen-bonded 2-chloro-1,10-phenanthroline—1,4-diiodotetrafluorobenzene (2/1), C30H14Cl2F4I2N4
  57. Crystal structure of 1-(4,4-dimethyl-2,6-dithioxo-1,3,5-triazinan-1-yl)-3-(diethylaminocarbonyl)thiourea, C11H20N6OS3
  58. Crystal structure of methyl 1-(4-fluorobenzyl)-3-phenyl-1H-pyrazole-5-carboxylate, C18H15FN2O2
  59. Crystal structure of 1,1-dimethyl-3-(4-methylphenyl)urea, C10H14N2O
  60. Crystal structure of yttrium gallium antimonide, Y5Ga1.24Sb2.77
  61. Crystal structure of 2-(bis(4-methoxyphenyl)amino)-2-oxoacetic acid, C16H15NO5
Heruntergeladen am 7.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0219/html
Button zum nach oben scrollen